Webinar - Understanding Pulmonary Hypertension in Left Heart Disease

Understanding Pulmonary Hypertension in Left Heart Disease

Click here to register

Pulmonary hypertension caused by left heart disease (Group 2 PH) is the most common form of PH, yet it is often misunderstood. In this webinar, we’ll explore what left heart disease is, how it leads to pulmonary hypertension, and what that means for patients.

🗓️ October 22 - 12:30 pm (PST) / 3:30 pm (EST)

Click here to register

Join Dr. Lisa Mielniczuk, an expert in the field, as she discusses:

1. Who is at risk for pulmonary hypertension in left heart disease

2. How it is diagnosed

3. Current treatment options and exciting new therapies under investigation

This interactive session will conclude with plenty of time for your questions.

Don’t miss this opportunity to deepen your understanding of Group 2 PH and the latest in patient care and research.

Dr. Lisa Mielniczuk completed her medical degree at McMaster University, a residency in Internal Medicine from Queen's University, and a Cardiology Fellowship at the University of Ottawa Heart Institute. She also completed a fellowship in advanced heart failure/cardiac transplantation at the Brigham and Women's Hospital in Boston, where she concurrently completed a Master's Degree in Clinical Science and Epidemiology at the Harvard School of Public Health. Dr. Mielniczuk was a Professor of Medicine at the University of Ottawa and the Director of the Advanced Heart Diseases Program at the Ottawa Heart Institute, with a cross-appointment to the Department of Cellular and Molecular Medicine, building a multi-disciplinary right heart failure research program. She was Vice-Chair for Quality and Clinical Care for the Department of Medicine from 2019-2024 and was the co-founder and Director of the Ottawa Pulmonary Hypertension Program. She has led several innovative clinical programs, including a Rapid Intervention Clinic for HF patients and a Regional HF program for the Ottawa/Champlain region.  Dr. Mielniczuk is an active leader for the HF and Pulmonary Hypertension community and is a past Chair for the Pulmonary Hypertension Association of Canada.